Trade Names:Latisse- Solution, ophthalmic 0.03%
Trade Names:Lumigan- Solution, ophthalmic 0.03%
Mechanism of action in treating hypotrichosis of the eyelids is unknown.Lumigan
May lower IOP by increasing outflow of aqueous humor through the trabecular meshwork and uveoscleral routes.
T max is within 10 min. Mean C max is about 0.08 ng/mL. Within 1.5 h after dosing, bimatoprost levels are below the lower limit of detection in most subjects. There is no systemic drug accumulation over time.
Moderately distributed to body tissues. Vd is 0.67 L/kg. Protein binding is about 88%.
Metabolism is via oxidation and glucuronidation to various metabolites.
Elimination half-life is approximately 45 min. Total blood Cl is 1.5 L/h/kg. Up to 67% is excreted by the kidneys and 25% is eliminated in the feces.
Treatment of hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.Lumigan
Reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
Ophthalmic Instill 1 drop in affected eye(s) in the evening.Hypotrichosis of the EyelashesAdults
Topical Once nightly, place 1 drop on the disposable sterile applicator and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. Use separate applicators for each eyelid.
Store at 36° to 77°F.
None well documented.
None well documented.
Asthenia, headaches (1% to 5%).
Skin hyperpigmentation (less than 4%).Lumigan
Abnormal hair growth (1% to 5%).
Conjunctival hyperemia, dry eye symptoms, erythema of the eyelid, eye pruritus, ocular irritation (less than 4%).Lumigan
Conjunctival hyperemia, growth of eyelashes, ocular pruritus (at least 15%); blepharitis, cataract, eye pain, eyelash darkening, eyelid erythema, foreign body sensation, ocular burning, ocular dryness, ocular irritation, pigmentation of the periorbital skin, superficial punctuate keratitis, visual disturbances (3% to 10%); allergic conjunctivitis, conjunctival edema, eye discharge, eye stain, increased iris pigmentation; photophobia, tearing (1% to 3%).
Abnormal LFTs (1% to 5%).
Upper respiratory tract infections (approximately 10%).
Monitor IOP when using Latisse for hypotrichosis of the eyelids.
Ensure that IOP has been measured and documented in the patient's record.
Category C .
Safety and efficacy not established.
No overall differences in safety and efficacy have been observed between elderly and other adult patients.
Use with caution in patients with iritis/uveitis.
Bacterial keratitis has been reported with multiple-dose containers as a result of patient contamination.
Instruct patients to remove contact lenses prior to administration and not to wear for 15 min following administration.
Upon discontinuation of treatment, eyelash growth is expected to return to the pretreatment level.
There is the potential for hair growth to occur in areas were bimatoprost solution comes in repeated contact with the skin surface. When applying bimatoprost topically, it is important to carefully blot any excess drug from the eyelid margin to avoid it running onto the cheek or other skin areas.
When instilled directly into the eye, IOP is lowered. Patients using prostaglandin analogs, including Lumigan to lower IOP should only use Latisse after consulting with their health care provider.
Use with caution in aphakic patients, pseudophakic patients with a risk of torn posterior lens capsule, or in patients with risk factors for macular edema.
Permanent changes to pigmented tissue may occur, most frequently involving pigmentation of the iris and eyelid and increased pigmentation and growth of eyelashes. Gradual change in eye color (ie, increased amount of brown pigmentation in the iris) may occur.
No information is available.
Copyright © 2009 Wolters Kluwer Health.